Alumis Inc.
ALMS
Rank in Stocks
#10188
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
Share Price
$6.41
Last synced: 2026-10-19
Market Cap
$830.25M
Change (1 day)
4.81%
Change (1 year)
182.57%
Country
US
Trade Alumis Inc. (ALMS)
Category
Healthcare
Stock split history for Alumis Inc. (ALMS)
Alumis Inc. stock (symbol: ALMS) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 20, 2026.
One ALMS share bought prior to Oct 20, 2026 would equal to 0 ALMS shares today.
The most recent stock split occurred on Oct 20, 2026.
One ALMS share bought prior to Oct 20, 2026 would equal to 0 ALMS shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
